R&D priorities: vaccines against Plasmodium vivax malaria

Vaccine
Volume 27, Issue 52, Pages 7219-7470 (9 December 2009)

Priorities in research and development of vaccines against Plasmodium vivax malaria
Pages 7228-7235
Graham V. Brown, Vasee S. Moorthy, Zarifah Reed, Kamini Mendis, Myriam Arévalo-Herrera, Pedro Alonso

Abstract
The WHO Initiative for Vaccine Research (IVR) Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on priorities in malaria vaccine research and development (R&D). This document summarizes a MALVAC scientific consultation of leading vaccine scientists on priorities in Plasmodium vivax vaccine R&D. The meeting discussed recent advances and key challenges in addressing identified gaps in knowledge. Major areas of discussion included disease burden estimates, clinical disease spectrum definitions, potential target product profiles and immunological and clinical research needed to better inform antigen selection and vaccine design. The need for further development of the human challenge model for P. vivax vaccines and specific considerations for conduct of field trials with P. vivax vaccines was outlined. This report summarizes the discussion and conclusions of the consultation, with recommendations for priority targeted research.

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.